8-K
filed April 8, 2026, 7:59 PM ET
ticker ENSC
CIK 0001716947
other material
confidence high
sentiment positive
materiality 0.65
Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55
Ensysce Biosciences, Inc.
- Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
- Conversion price fixed at $0.55 per share; warrants with 100% coverage (18-month and 5-year terms) at $0.55 exercise price.
- Amended Series B preferred stated value from $1,100 to $1,200 per share and issued 8,727,273 warrants.
- CEO Lynn Kirkpatrick states financing reflects continued investor confidence in the company's analgesic programs.
- Financing is part of up to $20M commitment available over 24 months from institutional investor.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.97
Ensysce Biosciences, Inc. issued 261,818 warrants to purchase shares of Common Stock of warrant to designees of financial advisor for similar terms as warrants issued to designees in November 2025; no additional consideration specified.
- Security
- warrant
- Shares
- 261,818 warrants to purchase shares of Common Stock
- Purchaser
- designees of financial advisor
- Consideration
- similar terms as warrants issued to designees in November 2025; no additional consideration specified
Exact text from the filing
The Company also issued Warrants to purchase up to 261,818 shares of Common Stock to designees of its financial advisor on similar terms as those warrants issued to the designees in November 2025.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Ensysce Biosciences, Inc. issued 2,000 shares of Series B Preferred Stock of preferred stock to institutional investor for gross proceeds of $2 million before deduction of fees and offering expenses.
- Security
- preferred stock
- Shares
- 2,000 shares of Series B Preferred Stock
- Purchaser
- institutional investor
- Consideration
- gross proceeds of $2 million before deduction of fees and offering expenses
Exact text from the filing
On April 6, 2026 (the " Closing Date "), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 shares (the " Shares ") of Series B preferred stock of the Company, par value $0.0001 per share (the " Preferred Stock "), (ii) up to 4,363,636 shares of common stock of the Company, par value $0.0001 per share (the " Common Stock ") to be issued upon conversion of the Preferred Stock, and (iii) warrants to purchase up to 8,727,273 shares of Common Stock (the " Warrants "), all subject to adjustment, for gross proceeds of $2 million before the deduction of fees and offering expenses (the " Offering ").
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Ensysce Biosciences, Inc. issued up to 4,363,636 shares of Common Stock issuable upon conversion of Preferred Stock of common stock to institutional investor for part of $2 million gross proceeds; conversion of Preferred Stock.
- Security
- common stock
- Shares
- up to 4,363,636 shares of Common Stock issuable upon conversion of Preferred Stock
- Purchaser
- institutional investor
- Consideration
- part of $2 million gross proceeds; conversion of Preferred Stock
Exact text from the filing
On April 6, 2026 (the " Closing Date "), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 shares (the " Shares ") of Series B preferred stock of the Company, par value $0.0001 per share (the " Preferred Stock "), (ii) up to 4,363,636 shares of common stock of the Company, par value $0.0001 per share (the " Common Stock ") to be issued upon conversion of the Preferred Stock, and (iii) warrants to purchase up to 8,727,273 shares of Common Stock (the " Warrants "), all subject to adjustment, for gross proceeds of $2 million before the deduction of fees and offering expenses (the " Offering ").
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Ensysce Biosciences, Inc. issued 8,727,273 warrants to purchase shares of Common Stock of warrant to institutional investor for part of $2 million gross proceeds.
- Security
- warrant
- Shares
- 8,727,273 warrants to purchase shares of Common Stock
- Purchaser
- institutional investor
- Consideration
- part of $2 million gross proceeds
Exact text from the filing
On April 6, 2026 (the " Closing Date "), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 shares (the " Shares ") of Series B preferred stock of the Company, par value $0.0001 per share (the " Preferred Stock "), (ii) up to 4,363,636 shares of common stock of the Company, par value $0.0001 per share (the " Common Stock ") to be issued upon conversion of the Preferred Stock, and (iii) warrants to purchase up to 8,727,273 shares of Common Stock (the " Warrants "), all subject to adjustment, for gross proceeds of $2 million before the deduction of fees and offering expenses (the " Offering ").
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Ensysce Biosciences, Inc. entered into Securities Purchase Agreement with institutional investor valued at $2 million gross proceeds for 2,000 shares of Series B preferred stock, up to 4,363,636 shares of co (effective 2026-04-06).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- institutional investor
- Value
- $2 million gross proceeds for 2,000 shares of Series B preferred stock, up to 4,363,636 shares of co
- Effective
- 2026-04-06
Exact text from the filing
As previously reported in a Current Report on Form 8-K filed on November 17, 2025, on November 13, 2025, Ensysce Biosciences, Inc. (the “ Company ” or “ we ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) directly with an institutional investor (the “ Purchaser ”). On April 6, 2026 (the “ Closing Date ”), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 shares (the “ Shares ”) of Series B preferred stock of the Company, par value $0.0001 per share (the “ Preferred Stock ”), (ii) up to 4,363,636 shares of common stock of the Company, par value $0.0001 per share (the “ Common Stock ”) to be issued upon conversion of the Preferred Stock, and (iii) warrants to purchase up to 8,727,273 shares of Common Stock (the “ Warrants ”), all subject to adjustment, for gross proceeds of $2 million before the deduction of fees and offering expenses (the “ Offering ”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.